Floatz logo

Natalizumab

Peritoneal Neoplasms

Institut du Cancer de Montpellier - Val d'AurelleN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

29 Active assets in the Peritoneal Neoplasms cohort.

Asset / SponsorPhaseRating
Irinotecan
Eli Lilly and Company
Phase 4BBB
Carboplatin
Eli Lilly and Company
Phase 3BBB
(+)-VINCRISTINE
Eli Lilly and Company
Phase 4BBB
Inno-206
Eli Lilly and Company
Phase 3BBB
FLUOROURACILUM
Sun Yat-sen University
Phase 2/3BB

View all 50 →

Same molecule, other indications

Natalizumab is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
79 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →
secondary progressive multiple sclerosisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →